RxDoctor Payments Data

Jagdeep Singh, MD

Internal Medicine · Ellicott City, MDNPI 1437195682

Payments from drug & device makers

$15,021in general payments, 2019–2025

Across 141 payments — averaging $106.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$6K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$5K
  • Abbott$1K
  • Novo Nordisk$478
  • Boston Scientific$471
  • AbbVie$446
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$6,18041%
  • Travel & lodging$2,77418%
  • Food & beverage$6,06740%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,021 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$227,465
Medicare patients
135
Services billed
2,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$86,801
OzempicSemaglutide36$41,233
MounjaroTirzepatide23$24,347
FarxigaDapagliflozin Propanediol14$18,275
Atorvastatin Calcium77$886
Lidocaine11$797
Celecoxib22$688
Pravastatin Sodium32$632
Telmisartan12$548
Methylprednisolone55$470
Metoprolol Succinate33$469
Losartan Potassium46$462
Amlodipine Besylate76$451
Pregabalin13$435
Diclofenac Sodium12$404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$118$86,80166 claims
Novo NordiskOzempic$478$41,23336 claims
Lilly USA, LLCMounjaro$304$24,34723 claims
AstraZenecaFarxiga$32$18,27514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Ellicott City

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →